AASLD practice guidance on drug,herbal,and dietary supplement-induced liver injury:also useful for hepatobiliary surgeons  

作　　者：Jose María Pinazo-Bandera Miren García-Cortés Raúl J.Andrade 

机构地区：[1]Service of Gastroenterology and Hepatology,University Hospital Virgen de la Victoria,Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma Bionand,Universidad de Málaga,Málaga,Spain [2]Centro de Investigación Biomédico en Red Enfermedades Hepáticas y Digestivas(CIBERehd),Madrid,Spain

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第5期746-751,共6页肝胆外科与营养（英文）

基　　金：supported by grants from Instituto de Salud Carlos III cofounded by Fondo Europeo de Desarrollo Regional-FEDER[contract numbers:FIS 21_01248;PI18/00901,UMA18-FEDERJA-193].CIBERehd is funded by Instituto de Salud Carlos III(ISCIII).All authors are members of the COST ACTION“CA-17112”-Prospective European Drug-Induced Liver Injury Network,supported by COST(European Cooperation in Science and Technology).www.cost.eu.JMPB holds a Rio Hortega contract from ISCIII.

摘　　要：Drug-induced liver injury(DILI)is a term used to describe an unexpected liver reaction to drugs,but also to herbal products and dietary supplements(HDS).In the current therapeutic armamentarium,only a small number of available drugs are still capable of causing liver damage in overdose.These include,in addition to paracetamol-the prototypical example of this group-niacin(now rarely used to treat hypercholesterolaemia),intravenous methotrexate and probably ketamine(an intravenous hypnotic used in critically ill patients for rapid sequence induction)(1).

关 键 词：Drug-induced liver injury(DILI) HEPATOTOXICITY causality assessment Revised Electronic Causality Assessment Method(RECAM) 

分 类 号：R575[医药卫生—消化系统]